Literature DB >> 22260507

Toll-like receptor (TLR) 3 immune modulation by unformulated small interfering RNA or DNA and the role of CD14 (in TLR-mediated effects).

Cordula Weber1, Christian Müller, Anja Podszuweit, Carmen Montino, Jörg Vollmer, Alexandra Forsbach.   

Abstract

The Toll-like receptors (TLRs) 3, 7, 8 and 9 stimulate innate immune responses upon recognizing pathogen-derived nucleic acids. TLR3 is located on the cell surface and in cellular endosomes and recognizes double-stranded viral RNA or the synthetic mimic poly rI:rC. Recently, unformulated small interfering RNA (siRNA) has been reported as ligand for surface-expressed murine TLR3. Blockage of TLR3 is achieved by single-stranded DNA. We confirm and expand the observation that poly rI:rC-mediated TLR3 immune activation is blocked in a sequence-, length-, backbone- and CpG-dependent manner. However, human TLR3 is not activated by siRNA, which may be the result of differences in the amino acid composition of the TLR3 loop 1 of mice and humans. Although CD14 was previously described as a co-receptor for murine TLR3 and other nucleic acid-recognizing TLRs, human CD14 acts only as co-receptor to human TLR9, but not TLR3, TLR7 or TLR8. We show that CD14 up-regulates the TLR9 immune response of A, B and C-class oligodeoxynucleotides but down-regulates the phosphoro-diester version of B-class oligodeoxynucleotides.
© 2012 The Authors. Immunology © 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22260507      PMCID: PMC3372758          DOI: 10.1111/j.1365-2567.2012.03559.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  76 in total

1.  SAR of a series of inhaled A(2A) agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data.

Authors:  Simon J Mantell; Peter T Stephenson; Sandra M Monaghan; Graham N Maw; Michael A Trevethick; Michael Yeadon; Don K Walker; Matthew D Selby; David V Batchelor; Stuart Rozze; Helene Chavaroche; Arnaud Lemaitre; Karen N Wright; Lynsey Whitlock; Emilio F Stuart; Patricia A Wright; Fiona Macintyre
Journal:  Bioorg Med Chem Lett       Date:  2009-05-12       Impact factor: 2.823

Review 2.  TLR accessory molecules.

Authors:  Sachiko Akashi-Takamura; Kensuke Miyake
Journal:  Curr Opin Immunol       Date:  2008-07-24       Impact factor: 7.486

3.  Sequence independent interferon-alpha induction by multimerized phosphodiester DNA depends on spatial regulation of Toll-like receptor-9 activation in plasmacytoid dendritic cells.

Authors:  Tobias Haas; Frank Schmitz; Antje Heit; Hermann Wagner
Journal:  Immunology       Date:  2008-11-15       Impact factor: 7.397

Review 4.  Pattern recognition by Toll-like receptors.

Authors:  Stefan Bauer; Thomas Müller; Svetlana Hamm
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

5.  Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth.

Authors:  Won Gil Cho; Romulo J C Albuquerque; Mark E Kleinman; Valeria Tarallo; Adelaide Greco; Miho Nozaki; Martha G Green; Judit Z Baffi; Balamurali K Ambati; Massimo De Falco; Jonathan S Alexander; Arturo Brunetti; Sandro De Falco; Jayakrishna Ambati
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-09       Impact factor: 11.205

6.  Double-stranded RNA induces an antiviral defense status in epidermal keratinocytes through TLR3-, PKR-, and MDA5/RIG-I-mediated differential signaling.

Authors:  Behnam Naderi Kalali; Gabriele Köllisch; Jörg Mages; Thomas Müller; Stefan Bauer; Hermann Wagner; Johannes Ring; Roland Lang; Martin Mempel; Markus Ollert
Journal:  J Immunol       Date:  2008-08-15       Impact factor: 5.422

7.  Single-stranded oligonucleotides can inhibit cytokine production induced by human toll-like receptor 3.

Authors:  C T Ranjith-Kumar; K E Duffy; J L Jordan; A Eaton-Bassiri; Robert Vaughan; Scott A Hoose; Roberta J Lamb; R T Sarisky; C Cheng Kao
Journal:  Mol Cell Biol       Date:  2008-05-19       Impact factor: 4.272

Review 8.  Treating lung inflammation with agonists of the adenosine A2A receptor: promises, problems and potential solutions.

Authors:  M A Trevethick; S J Mantell; E F Stuart; A Barnard; K N Wright; M Yeadon
Journal:  Br J Pharmacol       Date:  2008-09-01       Impact factor: 8.739

9.  Modulation of double-stranded RNA recognition by the N-terminal histidine-rich region of the human toll-like receptor 3.

Authors:  Kotaro Fukuda; Tomoya Watanabe; Takashi Tokisue; Tadayuki Tsujita; Satoshi Nishikawa; Tsunemi Hasegawa; Tsukasa Seya; Misako Matsumoto
Journal:  J Biol Chem       Date:  2008-06-10       Impact factor: 5.157

10.  Dual topology of functional Toll-like receptor 3 expression in human hepatocellular carcinoma: differential signaling mechanisms of TLR3-induced NF-kappaB activation and apoptosis.

Authors:  Kentaro Yoneda; Kazushi Sugimoto; Katsuya Shiraki; Junichiro Tanaka; Tetsuya Beppu; Hiroyuki Fuke; Norihiko Yamamoto; Masahiro Masuya; Ryo Horie; Kazuhiko Uchida; Yoshiyuki Takei
Journal:  Int J Oncol       Date:  2008-11       Impact factor: 5.650

View more
  26 in total

1.  Proteolytic processing regulates Toll-like receptor 3 stability and endosomal localization.

Authors:  Rongsu Qi; Divyendu Singh; C Cheng Kao
Journal:  J Biol Chem       Date:  2012-08-03       Impact factor: 5.157

2.  Mumps Virus SH Protein Inhibits NF-κB Activation by Interacting with Tumor Necrosis Factor Receptor 1, Interleukin-1 Receptor 1, and Toll-Like Receptor 3 Complexes.

Authors:  Stephanie Franz; Paul Rennert; Maria Woznik; Josephine Grützke; Amy Lüdde; Eva Maria Arriero Pais; Tim Finsterbusch; Henriette Geyer; Annette Mankertz; Nicole Friedrich
Journal:  J Virol       Date:  2017-08-24       Impact factor: 5.103

3.  Chimeric anti-CD14 IGG2/4 Hybrid antibodies for therapeutic intervention in pig and human models of inflammation.

Authors:  Corinna Lau; Kristin S Gunnarsen; Lene S Høydahl; Jan Terje Andersen; Gøril Berntzen; Anne Pharo; Julie K Lindstad; Judith K Ludviksen; Ole-Lars Brekke; Andreas Barratt-Due; Erik Waage Nielsen; Christopher R Stokes; Terje Espevik; Inger Sandlie; Tom Eirik Mollnes
Journal:  J Immunol       Date:  2013-09-23       Impact factor: 5.422

4.  Improvement of DC-based vaccines using adjuvant TLR4-binding 60S acidic ribosomal protein P2 and immune checkpoint inhibitors.

Authors:  Tae Heung Kang; Yeong-Min Park; Gun-Young Jang; Young Seob Kim; Sung Eun Lee; Ji Won Lee; Hee Dong Han
Journal:  Cancer Immunol Immunother       Date:  2020-10-28       Impact factor: 6.968

5.  Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering.

Authors:  Jesper B Bramsen; Jørgen Kjems
Journal:  Front Genet       Date:  2012-08-20       Impact factor: 4.599

6.  CD14 and complement crosstalk and largely mediate the transcriptional response to Escherichia coli in human whole blood as revealed by DNA microarray.

Authors:  Corinna Lau; Ståle Nygård; Hilde Fure; Ole Kristoffer Olstad; Marit Holden; Knut Tore Lappegård; Ole-Lars Brekke; Terje Espevik; Eivind Hovig; Tom Eirik Mollnes
Journal:  PLoS One       Date:  2015-02-23       Impact factor: 3.240

7.  UNC93B1 mediates differential trafficking of endosomal TLRs.

Authors:  Bettina L Lee; Joanne E Moon; Jeffrey H Shu; Lin Yuan; Zachary R Newman; Randy Schekman; Gregory M Barton
Journal:  Elife       Date:  2013-02-19       Impact factor: 8.140

8.  Design of siRNA Therapeutics from the Molecular Scale.

Authors:  Phillip Angart; Daniel Vocelle; Christina Chan; S Patrick Walton
Journal:  Pharmaceuticals (Basel)       Date:  2013

Review 9.  Role of CD14 in host protection against infections and in metabolism regulation.

Authors:  Ivan Zanoni; Francesca Granucci
Journal:  Front Cell Infect Microbiol       Date:  2013-07-24       Impact factor: 5.293

10.  Innate immunity activation involved in unprotected porcine auto-transplant kidneys preserved by naked caspase-3 siRNA.

Authors:  Cheng Yang; Long Li; Yinjia Xue; Zitong Zhao; Tian Zhao; Yichen Jia; Ruiming Rong; Ming Xu; Michael L Nicholson; Tongyu Zhu; Bin Yang
Journal:  J Transl Med       Date:  2013-09-13       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.